IP Library Granted Patent US 10,596,167
Granted Patent B2
US 10,596,167 · App. 16/133,553 · Granted Mar 24, 2020

Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/485A61K31/135A61K31/137
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,596,167
App. No.
16/133,553
Granted
Mar 24, 2020
Kind
B2
Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claims (26)

1. A method, comprising treating a human being with dextromethorphan by administering once daily or twice daily for at least eight consecutive days a single dosage form comprising both dextromethorphan and bupropion to the human being, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the dosage form contains about 40 mg to about 100 mg of dextromethorphan and the weight ratio of dextromethorphan to bupropion is about 0.2 to about 1.0, and wherein after eight consecutive days of administering the dosage form once daily or twice daily, the method results in an AUC 0-12 of dextromethorphan that is: 1) at least about 500 ng·hr/mL and 2) at least 15 times the AUC 0-12 of dextromethorphan that would be achieved by administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

2. The method of claim 1 , wherein the dosage form is an oral dosage form.

3. The method of claim 1 , wherein the dosage form is a solid dosage form that further comprises a binder.

4. The method of claim 1 , wherein the dosage form is a solid dosage form that further comprises a disintegrating agent.

5. The method of claim 1 , wherein the dosage form is a solid dosage form that further comprises a lubricant.

6. The method of claim 1 , wherein the dosage form comprises a liquid or solid phase dispersion of bupropion and dextromethorphan.

7. The method of claim 1 , wherein the dosage form is effective for immediate release of dextromethorphan.

8. The method of claim 1 , wherein the dosage form is effective for sustained release of bupropion.

9. The method of claim 1 , wherein after eight consecutive days of administering the dosage form once daily or twice daily, the AUC 0-12 of dextromethorphan is about 500 ng·hr/mL to about 600 ng·hr/mL.

10. The method of claim 1 , wherein after eight consecutive days of administering the dosage form once daily or twice daily, the AUC 0-12 of dextromethorphan is about 800 ng·hr/mL to about 900 ng·hr/mL.

11. The method of claim 1 , wherein after eight consecutive days of administering the dosage form once daily or twice daily, the AUC 0-12 of dextromethorphan is at least about 20 times the AUC 0-12 of dextromethorphan that would be achieved by administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

12. The method of claim 1 , wherein the once daily or twice daily administration of the dosage form results in a total daily dose of bupropion that is about 150 mg to about 200 mg.

13. The method of claim 1 , wherein the once daily or twice daily administration of the dosage form results in a total daily dose of bupropion that is about 200 mg to about 250 mg.

14. The method of claim 1 , wherein the once daily or twice daily administration of the dosage form results in a total daily dose of bupropion that is about 250 mg to about 300 mg.

15. The method of claim 1 , wherein the once daily or twice daily administration of the dosage form results in a total daily dose of dextromethorphan that is about 60 mg to about 100 mg.

16. A method for treating a human being with dextromethorphan, comprising administering to the human being a combination of dextromethorphan and bupropion in a single dosage form once daily or twice daily for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the dosage form contains about 40 mg to about 100 mg of dextromethorphan and the weight ratio of dextromethorphan to bupropion is about 0.2 to about 1.0, and wherein, after the combination is administered once daily or twice daily for eight consecutive days: 1) the human being has a C max of dextromethorphan that is at least about 40 ng/mL and 2) the C max of dextromethorphan is at least about 15 times the C max of dextromethorphan that would result from administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

17. The method of claim 16 , wherein the C max of dextromethorphan on the eighth day that the combination is administered is at least about 20 times the C max of dextromethorphan that would result from administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

18. The method of claim 16 , wherein the C max of dextromethorphan on the eighth day that the combination is administered is about 50 ng/mL to about 60 ng/mL.

19. The method of claim 16 , wherein the C max of dextromethorphan on the eighth day that the combination is administered is about 80 ng/mL to about 90 ng/mL.

20. The method of claim 16 , wherein the single dosage form containing the combination is an oral dosage form.

21. The method of claim 16 , wherein the single dosage form containing the combination is a solid oral dosage form that further comprises a binder.

22. The method of claim 16 , wherein the single dosage form containing the combination is a solid oral dosage form that further comprises a disintegrating agent.

23. The method of claim 16 , wherein the single dosage form containing the combination is a solid oral dosage form that further comprises a lubricant.

24. The method of claim 16 , wherein the single dosage form containing the combination is a solid oral dosage form that is effective for immediate release of dextromethorphan and sustained release of bupropion.

25. The method of claim 20 , wherein the once daily or twice daily administration of the combination results in a total daily dose of bupropion that is about 200 mg to about 250 mg.

26. The method of claim 20 , wherein the once daily or twice daily administration of the combination results in a total daily dose of dextromethorphan that is about 60 mg to about 100 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2018
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 047518/0581 →
Continuity (15)
Continuation 15695995 · Sep 5, 2017
Continuation 15238182 · Aug 16, 2016
Continuation In Part 14997316 · Jan 15, 2016
Continuation In Part 14555085 · Nov 26, 2014
Continuation 14550618 · Nov 21, 2014
Continuation In Part PCTUS2014064184 · Nov 5, 2014
Continuation In Part 15213283 · Jul 18, 2016
Continuation In Part 15057983 · Mar 1, 2016
Continuation In Part 14863284 · Sep 23, 2015
Provisional Application 61900354 · Nov 5, 2013
Provisional Application 62336533 · May 13, 2016
Provisional Application 62323438 · Apr 15, 2016
Provisional Application 62313620 · Mar 25, 2016
Provisional Application 62313067 · Mar 24, 2016
Related Publication 20190015407A1 · Jan 17, 2019
Cited By (25)
US 12,194,005 US 12,194,006 US 12,194,036 US 12,239,642 US 12,263,161 US 12,310,961 US 12,357,697 US 12,364,674 US 12,370,154 US 12,377,091 US 12,390,428 US 12,433,884 US 12,447,138 US 12,472,155 US 12,472,156 US 12,472,174 US 12,478,622 US 12,544,345 US 12,564,587 US 12,569,479 US 12,576,078 US 12,599,576 US 12,653,795 US 12,661,408 US 12,678,506